Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names
- PMID: 28550031
- PMCID: PMC5553954
- DOI: 10.1634/theoncologist.2017-0041
Curative, Life-Extending, and Palliative Chemotherapy: New Outcomes Need New Names
Abstract
Imprecise terminology obscures the reasons why a cancer patient might be willing to endure the potential toxicities and side‐effects of treatment. Renaming of the categories of chemotherapy is proposed here to clarify intended definitions.
Conflict of interest statement
Disclosures of potential conflicts of interest may be found at the end of this article.
References
-
- Browner I, Carducci MA. Palliative chemotherapy: Historical perspective, applications, and controversies. Semin Oncol 2005;32:145.–. - PubMed
-
- Archer VR, Billingham LJ, Cullen MH. Palliative chemotherapy: No longer a contradiction in terms. The Oncologist. 1999;4:470.–. - PubMed
-
- Clamon GH, Corder MP. ABVD treatment of MOPP failures in Hodgkin's disease: A re‐examination of goals of salvage therapy. Cancer Treat Rep 1978;62:363.–. - PubMed
-
- Portlock CS, Rosenberg SA, Glatstein E et al. Impact of salvage treatment on initial relapses in patients with Hodgkin disease, stages I‐III. Blood 1978;51:825.–. - PubMed
-
- Morel A, Josserand A, Detry R. [Perfection of a method of palliative chemotherapy of certain epithelial cancers]. Lyon Med 1950;183:3.–. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
